- $766.81m
- $885.54m
- $27.12m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 28.28 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.68% | ||
| Return on Equity | -238.46% | ||
| Operating Margin | -679.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 37.51 | 524 | 106.48 | 15.84 | 27.12 | 44.16 | 124.51 | 30.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Directors
- Matthew Kapusta CEO (48)
- Christian Klemt CFO (48)
- Ricardo Dolmetsch CEX (52)
- Pierre Caloz COO
- Alexander Kuta EVP (61)
- Rachelle Jacques DRC (50)
- Robert Gut NED (56)
- Madhavan Balachandran NID (70)
- Jack Kaye NID (77)
- David Meek NID (58)
- Leonard Post NID (68)
- Paula Soteropoulos NID (53)
- Jeremy Springhorn NID (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 9th, 2012
- Public Since
- February 5th, 2014
- No. of Shareholders
- 3
- No. of Employees
- 209
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 54,076,880
- Address
- Paasheuvelweg 25a, AMSTERDAM, 1105 BP
- Web
- https://www.uniqure.com/
- Phone
- +31 202406000
- Contact
- Maria Cantor
- Auditors
- KPMG Accountants N V
Upcoming Events for QURE
Uniqure NV Annual Shareholders Meeting
Similar to QURE
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Uniqure NV share price?
As of Today at 23:52 UTC, shares in Uniqure NV are trading at $14.18. This share price information is delayed by 15 minutes.
How has the Uniqure NV share price performed this year?
Shares in Uniqure NV last closed at $14.18 and the price had moved by +212.33% over the past 365 days. In terms of relative price strength the Uniqure NV share price has outperformed the S&P500 Index by +188.3% over the past year.
What are the analyst and broker recommendations for Uniqure NV?
The overall consensus recommendation for Uniqure NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Uniqure NV dividend yield?
Uniqure NV does not currently pay a dividend.
Does Uniqure NV pay a dividend?
Uniqure NV does not currently pay a dividend.
When does Uniqure NV next pay dividends?
Uniqure NV does not currently pay a dividend.
How do I buy Uniqure NV shares?
To buy shares in Uniqure NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Uniqure NV?
As of the previous close price of $14.18, shares in Uniqure NV had a market capitalisation of $766.81m.
Where are Uniqure NV shares listed?
Here are the trading details for Uniqure NV:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: QURE
What kind of share is Uniqure NV?
Based on an overall assessment of its quality, value and momentum Uniqure NV is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Uniqure NV share price forecast for 2025?
The analyst consensus target price for shares in Uniqure NV is $36.70. That is 158.82% above the last closing price of $14.18.
Analysts covering Uniqure NV currently have a consensus Earnings Per Share (EPS) forecast of -$3.90 for the next financial year.
Find out moreWhat is the trend in the Uniqure NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Uniqure NV. Over the past six months, its share price has outperformed the S&P500 Index by +128.7%.
As of the last closing price of $14.18, shares in Uniqure NV were trading +43.33% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Uniqure NV PE Ratio?
The Uniqure NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $14.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Uniqure NV?
Uniqure NV's management team is headed by:
- Matthew Kapusta - CEO
- Christian Klemt - CFO
- Ricardo Dolmetsch - CEX
- Pierre Caloz - COO
- Alexander Kuta - EVP
- Rachelle Jacques - DRC
- Robert Gut - NED
- Madhavan Balachandran - NID
- Jack Kaye - NID
- David Meek - NID
- Leonard Post - NID
- Paula Soteropoulos - NID
- Jeremy Springhorn - NID